

Article

Computer Analysis of the Inhibition of ACE2 by Flavonoids and Identification of Their Potential Antiviral Pharmacophore Site

Andrey Bogoyavlenskiy ^{1,*}, Madina Alexyuk ¹, Pavel Alexyuk ¹, Vladimir Berezin ¹, Faisal A. Almalki ², Taibi Ben Hadda ^{2,3,*}, Alaa M. Alqahtani ², Saleh A. Ahmed ⁴, Stefano Dall'Acqua ⁵ and Joazaizulfazli Jamalil ^{6,*}

- ¹ Research and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan; madina.a06@gmail.com (M.A.); pagenal@bk.ru (P.A.); vberezin359@gmail.com (V.B.)
- ² Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia; malkifaisal2@gmail.com (F.A.A.); amqahtani@uqu.edu.sa (A.M.A.)
- ³ Laboratory of Applied Chemistry & Environment, Faculty of Sciences, Mohammed Premier University, MB 524, Oujda 60000, Morocco
- ⁴ Department of Chemistry, Faculty of Applied Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia; saahmed@uqu.edu.sa
- ⁵ Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35121 Padova, Italy; stefano.dallacqua@unipd.it
- ⁶ Department of Chemistry, Faculty of Science, Universiti Teknologi Malaysia, UTM, Johor Bahru 81310, Johor, Malaysia
- * Correspondence: anpav_63@mail.ru (A.B.); taibi.ben.hadda@gmail.com (T.B.H.); joazaizulfazli@utm.my (J.J.)

Abstract: In the present study, we investigated the antiviral activities of 17 flavonoids as natural products. These derivatives were evaluated for their in vitro antiviral activities against HIV and SARS-CoV-2. Their antiviral activity was evaluated for the first time based on POM (Petra/Osiris/Molinspiration) theory and docking analysis. POM calculation was used to analyze the atomic charge and geometric characteristics. The side effects, drug similarities, and drug scores were also assumed for the stable structure of each compound. These results correlated with the experimental values. The bioinformatics POM analyses of the relative antiviral activities of these derivatives are reported for the first time.

Keywords: plant compounds; flavonoids; inhibition of the ACE2 protein; docking; POM (Petra/Osiris/Molinspiration) analyses



Citation: Bogoyavlenskiy, A.; Alexyuk, M.; Alexyuk, P.; Berezin, V.; Almalki, F.A.; Ben Hadda, T.; Alqahtani, A.M.; Ahmed, S.A.; Dall'Acqua, S.; Jamalil, J. Computer Analysis of the Inhibition of ACE2 by Flavonoids and Identification of Their Potential Antiviral Pharmacophore Site. *Molecules* **2023**, *28*, 3766. <https://doi.org/10.3390/molecules28093766>

Academic Editor: Francisco Torrens

Received: 12 April 2023

Revised: 25 April 2023

Accepted: 25 April 2023

Published: 27 April 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The renin-angiotensin-aldosterone system (RAAS) is one of the human body's main systems and is of crucial importance in the regulation of most physiological and pathophysiological conditions, including vascular tone and blood pressure (BP), remodeling of the vascular wall and heart muscle, mechanisms of development and progression of atherosclerosis, glomerulosclerosis, and other pathologies [1–5]. Hyperactivity of the local (tissue) RAAS, the components of which are synthesized directly in various organs and tissues (heart, kidneys, eyes, adipose tissue, pancreas), can cause Kahn, Liddle, and Bartter syndromes, ischemic nephropathy, and diabetes mellitus [5,6]. This system was especially promising in 2020 after the discovery that one of the receptors of the SARS-CoV-2 virus is the angiotensin-converting enzyme 2 (ACE2), binding to which promotes the transport of the virus into the host cell [7,8]. Due to the widespread prevalence of COVID-19 around the world, the question of a detailed study of one of the key links in the pathogenesis of coronavirus infection, involving the ACE2 protein, is especially relevant. A detailed study of the enzyme, which is a receptor on the surface of various tissues and normally converts angiotensin II into angiotensin, has led to ambiguous conclusions. Being non-tissue-specific, the receptor is widely distributed in the heart, kidneys, small intestine, ovaries, thyroid

gland, and adipose tissues. In addition to its direct bioregulatory function, it suppresses inflammation, mainly in lung tissue, participates in the transport of amino acids, and supports the vital activity of the intestinal microbiome. Thus, the ACE2 protein plays an essential role in several metabolic processes in the body. Simultaneously, along with performing many positive functions, the ACE2 protein promotes binding and transport to the host cell of the SARS-CoV-2 virus, which makes it possible to consider it a target for influencing coronavirus infection [9–15].

The use of inhibitors that affect the renin–angiotensin system may be a promising therapeutic strategy for combating coronavirus infection. Preliminary data on the use of ACE2 inhibitors, drugs containing this receptor in circulatory form, and angiotensin receptor II blockers indicate their effectiveness and the possibility of improving the condition and prognosis of patients with coronavirus infection taking ACE2 inhibitors [10,11].

Thus, when developing drugs to combat coronavirus infection, inhibitors of the ACE2 protein can be considered a promising group of compounds for the creation of new antiviral agents. The search for effective ACE2 blockers among various natural compounds can be conducted empirically using traditional viral models. However, this approach requires a large amount of work and considerable material costs. Therefore, in the first stage of assessing the potential capabilities of compounds, it seems appropriate to simulate their activity by molecular docking using computer programs. The promising structures selected based on the results of such a study can then be studied in more detail using appropriate experimental models, which will reduce both material costs and development time [16–18].

In the present work, computer docking and POM analyses of several polyphenolic and triterpenoid compounds were carried out and their possible effect on angiotensin converting enzyme 2 (ACE2), which contributes to the transport of the COVID-19 virus into the host cell, was evaluated. The POM theory was of great help in the identification of two antiviral pharmacophore sites ($O^{\delta-}$, $O'^{\delta-}$, $O''^{\delta-}$) that are regenerated from parent flavonoids and their metabolites.

2. Results and Discussion

2.1. Docking Analysis

The choice of the ACE2 protein model was associated with the possible determination of the mechanism of action of the ligand on either orthosteric or allosteric sites of ACE2 protein activity. Therefore, the Native Human Angiotensin Converting Enzyme-Related Carboxypeptidase (ACE2)-1R42 model was chosen to analyze possible inhibition (Figure 1) [19].




Figure 1. The structure of the ACE 2 protein.

A computer simulation of the interaction of 50 plant compounds of various chemical natures with the ACE2 protein was carried out, and the binding activity of the studied structures with the protein was evaluated. The analysis considered the position at which the binding energy of the protein to the ligand was the best (lowest in kcal/mol).

The interaction activity of the analyzed drugs was compared with that of standard drugs used to inhibit ACE2. Computer analysis of the selected compounds revealed that the energy used for the ligand binding to the protein ranged from -7 to -10 kcal/mol (Table 1).

Table 1. Binding energy of the selected ligands with the studied protein.

No.	Ligand	Binding Energy (kcal/mol)
1	Rhamnetin (3,3',4',5-Tetrahydroxy-7-methoxyflavone)	-8.1
2	Patuletin (3,3',4',5,7-Pentahydroxy-6-methoxyflavone)	-7.7
3	Isorhamnetin (3,4',5,7-Tetrahydroxy-3'-methoxyflavone)	-7.7
4	Tamarixetin (3,3',5,7-Tetrahydroxy-4'-methoxyflavone)	-7.8
5	Quercetin (3,3',4',5,7-Pentahydroxyflavone)	-7.6
6	Corniculatusin (3,3',4',5,7-Pentahydroxy-8-methoxyflavone)	-8.2
7	Dillenetin (3,4-Dimethoxy-3,5,7-trihydroxyflavone)	-7.5
8	Nobiletin (3',4',5,6,7,8-Hexamethoxyflavone)	-7.8
9	Hesperidin (7-Rhamnoglucoside)	-9.6
10	Baicalein (5,6,7-Trihydroxyflavone)	-8.1
11	Ayanin (5,3'-Dihydroxy-3,7,4'-trimethoxyflavone)	-7.4
12	Azaleatin (3,3',4',7-Tetrahydroxy-5-methoxyflavone)	-7.6
13	Ombuin (4',7-Dimethoxy-3,3',5-trihydroxyflavone)	-7.8
14	Pachypodol (4',5-Dihydroxy-3,3',7-trimethoxyflavone)	-7.2
15	Retusin (5-Hydroxy-3,3',4',7-tetramethoxyflavone)	-7.3
16	Rhamnazin (Dimethoxyflavone)	-7.8
17	Eupatolitin (3,3',4',5-Tetrahydroxy-6,7-dimethoxyflavone)	-7.8
18	Captopril	-6.5
19	MLN4760	-7.4
20	Lisinopril	-8.0
21	Amlodipin	-7.3

Based on the fact that the selected standard comparison drugs used to inhibit ACE2 in order to reduce pressure had binding energy ranging from -6 to -8 kcal/mol (captopril, MLN4760, Lisinopril, Amlodipin), we determined the cut-off value of the binding energy of the protein to the ligand as -7.4 kcal/mol. The use of this threshold value allowed us to identify 17 compounds with potentially high inhibitory properties in relation to the ACE2 protein (Table 1).

Compounds with a binding energy of the protein to the ligand below the selected cut-off value were divided into two equal groups, the first of which mainly interacted with the second allosteric activity center of the ACE2 protein and the second of which mainly interacted with the third allosteric activity center (Tables 2 and S1).

Table 2. Features of the interaction of ACE2 protein with the ligand.

No.	Hydrogen Bonds	Van der Waals Force	Allosteric Site Surrounding Amino Acids Residues
1	Asp206, Trp566, Asn210	Asn397, Lys562, Ala99, Ala396, Glu208, Pro565, Leu95, Val212, Val209	2
2	Tyr196, Glu564, Ala396, Lys562, Glu208	Leu95, Pro565, Asp206, Glu98, Gly205, Gln98, Gln102, Tyr202	2
3	Gly208, Tyr196, Gly205, Lys502	Asp206, Ala99, Leu392, Leu95	2
4	Tyr385, Asp350, Asp382, Aka348	His378, Arg393, Phe390, Phe40, Asn394, His401	3
5	Asp206, Asn210, Trp566	Asn397, Lys562, Ala396, Gln208, Val212, Leu95, Val209, Pro565	2
6	Asp206, Asp210, Trp566	Ala396, Asn397, Lys562, Gln98, Pro565, Val209, Gln208, Leu95, Val212	2
7	Trp566, Lys562	Val209, Gln564, Pro565, Leu95, Gln98, Asp206, gln208, Gly205, Tyr196, Tyr202, Gln102	2
8	Asn210	Val212, Val209, Leu95, Pro565, Lys562, Gln205, Asp206, Tyr202, Tyr196, Gln208, Gln91, Lys94, Gln102	2
9	Ala248, Gln402, Glu375, Tyr385, Asp350, Ser47, Ser43	Trp69, Gly68, Phe40, Asp382, Asn394, Trp349, His401, His378, Thr347	3
10	Trp566, Ala396, Asp206	Lys562, Leu95, Val209, Asn210, Pro565, Glu564, Asn397	2
11	Tyr196	Trp203, Gln102, Tyr202, Gly205, Asp206, Gln98, Leu95, Lys562, Glu208	2
12	Asp509, Ser511, Tyr199, Tyr196, Gln102	Tyr510, Trp203, Asp514, Asp206, Tyr202	2
13	Asp350, Asp382, Ala348	Arg393, Phe390, Phe40, Asn394, His401, His378, Tyr385	3
14	Lys562, Tyr196	Trp566, Pro565, Val209, Gln208, Leu392, Leu95, Ala99, Glu208	2
15	Tyr196	Tyr202, Trp203, Asp206, Gly205, Leu95, Glu564, Lys562, Gln208, Gln98, Ala396	2
16	Trp566, Ala396, Gln102	Asn210, Val209, Asp206, Lys562, Pro565	2
17	Trp566, Glu564, Lys562, Gln98, Tyr196	Pro565, Leu95, Asp206, Gln102, Tyr202	2

The RAAS is of paramount importance in the regulation of most physiological and pathophysiological conditions, from the level of blood pressure (BP) to the mechanisms of development and progression of atherosclerosis [1–4]. Therefore, the main enzymes of this system, as a rule, can affect both orthostatic and allosteric regulation. This feature of angiotensin-converting enzyme type 2 (ACE2), which has an orthosteric and three allosteric sites of activity [20,21], creates both pros and cons in the search for new compounds affecting this protein using computer modeling methods.

Highly conserved amino acid residues Lys 31, Glu35, Asp38, Met82, and Lys353 were identified in the ACE 2 structure, four of which were located in the N-terminal part of the ectodomain of the enzyme responsible for interaction with the COVID-19 S protein [22]. Therefore, ligand binding to amino acids ACE2 30–41 a.r.; 82–84 a.r.; 353–357 a.r. will directly affect the possibility of S protein SARS-CoV-2 attachment to ACE2 during invasion of the host cell. At the same time, it was found that the spike protein from SARS-CoV-2 attaches to ACE 2 in a place other than the active site of the peptidase ACE2 [23], which somewhat reduces the possibility of using statins to alter the course of coronavirus infection.

The search for compounds affecting the orthosteric site of ACE2 showed that these are mainly short peptides or drugs, based on the use of monoclonal or polyclonal antibod-

ies [20,21]. Simultaneously, the presence of three allosteric sites located on both sides of the orthosteric site and having an additional field for interaction with amino acids creates additional opportunities for identifying new compounds capable of suppressing the sorption of SARS-CoV-2 on the surface of competent cells. In our study, 17 compounds that can effectively interact with the ACE 2 molecule were identified. Analysis of the ability to form hydrogen bonds or bind via Van der Waals forces with enzyme molecules showed that the studied compounds were clearly divided into two main groups. The first includes a group of flavones that can interact with sites from one to several amino acids of the allosteric site of the ACE2 molecule. The second group of compounds not only interacts with amino acids of the allosteric site of the enzyme molecule but is also able to form bonds of various origins with amino acids of the orthosteric site of ACE2.

Thus, it was shown that computer modeling makes it possible not only to detect whether a ligand is able to interact with a particular protein but also to evaluate the mechanism of action of such compounds. The results obtained can be used for the preliminary assessment of the activity of compounds in the development of new effective drugs.

2.2. POM Analyses

POM Theory (Petra/Osiris/Molinspiration), which was proposed by a group led by Taibi Ben Hadda in collaboration with the American NCI and TAACF, has led to great success in the pharmacology and drug-design fields of antibacterial, antifungal, antiviral, and antiparasitic agents [24–92].

Here, we treated a series of natural products 1–17 with the goal of identifying their antiviral pharmacophore sites according to the POM organigram. The identification of pharmacophore sites for these compounds was derived from the physical and chemical properties of the tested compounds using a bioinformatics POM platform (Figure 2).




Figure 2. The Concept and Applications of POM Theory [78].

2.2.1. Osiris Calculations of Compounds 1–17

The results of the pharmacokinetic properties and bioactivity score analysis are shown in the supplementary information, Figure S1 and Table S2. The drug score was very encouraging ($30\% < DS < 75\%$). The toxicity risks and molecular characteristics of 1–17 were estimated. All structures examined were found to be non-tumorigenic and non-toxic-reproductive, but mutagenic. It seems that only 2 of the 17 compounds were safe, and the majority of compounds 1–17 exhibited side effects. This led us to find more indications of metabolites with better scores.

2.2.2. Molinspiration Calculations of Compounds 1–17

The result of the Molinspiration analysis is presented in the supplementary information, Table S3. These bioactivity scores could be categorized as active (if the score was >0), moderately active (if the score was -5.0 to 0.0), or inactive (if the score was less than -5.0). Corroboration of all bioactivity parameters showed that the majority of the flavonoid derivatives were biologically active against all of the enzymes involved (Table S4).

2.2.3. Atomic Charge Calculation of Compounds 1–17

According to the results of the calculations of atomic charge shown in the supplementary information, Figure S2, it is clear that most compounds 1–17 have an ($O^{\delta-}$, $O'^{\delta-}$, $O''^{\delta-}$) antiviral pharmacophore site. Because of this, most hits are related to antiviral agents rather than antifungal or antibacterial agents. As a result, it was identified as a pharmacophore site with antiviral properties for compounds 1–17 (Figure 3).




Figure 3. Proposed mechanism of opening and closing central ring C and identification of the antiviral pharmacophore sites for compounds 1–17 [POM].

2.2.4. Identification of Antiviral Pharmacophore Sites

The flavonoids 1–17 have been described as subjects of opening/closing ring C and present moderate to good antiviral activity scores, according to the results of the experimental and theoretical POM calculations (Figure 3).

3. Materials and Methods

Molecular modeling of the interaction of the analyzed compounds with the ACE2 protein was carried out using a computer analysis of the ligand-binding activity to the target. Such modeling makes it possible to place the ligand in the preferred binding site of the protein and to evaluate the specificity and binding efficiency by determining the interaction energy of the components. The information obtained through molecular docking can be used to predict the free binding energy and stability of the complexes. The main goal of molecular docking is to obtain a protein–ligand complex with an optimized conformation and lower binding free energy.

For the practical application of molecular docking, a data bank is required to search for a target with the appropriate PDB format and a methodology for preparing the ligand in the form of a PDB file. Various programs are available in which the ligand can be converted to the PDB format. In our case, ligand preparation was carried out in the PyMol program 2.5.2 (<https://pymol.org/2/>, accessed 2 February 2022) [93–99]. Before direct modeling, the target and the ligand were prepared. To do this, the established structure of the selected protein underwent significant changes and was converted to the PDBQT format using the AutoDock Tools program 1.5.6. Subsequently, each ligand was also converted to the PDBQT format. The computer simulation itself was carried out using the AutoDock Vina program 1.1.2 (<http://vina.scripps.edu/>, accessed 2 February 2022), as well as external tools such as AutoDock Tools (<http://mgltools.scripps.edu/downloads>, accessed 2 February 2022) [98,99].

In this program, the protein combines with one of the ligands to form a protein–ligand complex. After entering the data, the program automatically generates a grid of the active center of the protein after which an algorithm is prescribed in the command line to determine the active sites of the ligand. As a result, the AutoDock Vina program 1,1,2 identified nine active ligand positions, with the best position being in the region with the lowest binding energy (BE) in kcal/mol. Visualization of the protein–ligand complex itself can be performed using various programs. We performed 2D visualization of the ACE2 protein with a ligand in the LigPlot+ program 2.2.5. This program allows for better visualization of the connection between the protein and ligand. This determines the amino acids that are directly linked to the ligand (<https://www.ebi.ac.uk/thornton-srv/software/LigPlus/download2.html>, accessed 2 February 2022) [98,99].

For a comparative study, 54 compounds were used, including four compounds used as blockers of the ACE2 protein at elevated pressure. The choice of compounds was determined based on previous studies (data are not presented) showing high efficacy of glycoside derivatives of flavonoids, methoxyflavonoids, and triterpene compounds.

4. Conclusions

We conducted a computational docking and POM study to identify the pharmacophore sites of 17 flavonoids, known as anti-viral agents. All flavonoids were successfully analyzed *in silico* for antiviral activity prediction, POM calculation, molecular docking, and pharmacokinetic properties. The insertion of various aliphatic and aromatic groups into the basic flavonoid structure can considerably improve its biological and antiviral activities. Antiviral prediction indicated that aliphatic/aromatic (1–17) derivatives exhibit potential antiviral effects. These findings were rationalized through molecular docking, which revealed the excellent antiviral efficacy of flavonoid derivatives. Many derivatives have shown outstanding binding energy and binding interactions with biotargets. Most flavonoid derivatives exhibited good potential *in silico* to inhibit HIV. The derivatives were unraveled in a stable binding conformation in the docked pocket, engaged by both hydrophobic and hydrophilic interactions. Future *in vitro* and *in vivo* studies are needed to determine whether these derivatives can be used to treat SARS-CoV-2 and HIV. The POM study confirmed the predominant antiviral profile of most compounds in series 1–17. This is highly encouraging to screen the antiviral hits as potential antiviral candidates.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules28093766/s1>, Table S1a: 2D and 3D visualization of ligand binding to the protein under study; Table S1b: 2D and 3D visualization of ligand binding to the protein under study; Table S1c: 2D and 3D visualization of ligand binding to the protein under study; Table S2: Comparison of Toxicity Risks and Drug Score of compounds 1–17; Table S3: Molinspiration calculations for compounds 1–17; Table S4: Comparison of Molinspiration data for compounds 1–17; Figure S1: Osiris calculations of likeness and drug-score of compounds (1–17); Figure S2: Atomic charge calculations for compounds 1–17.

Author Contributions: The study in this manuscript was collaboratively executed by all aforementioned authors. The authors' contributions are summarized as follows; J.J., A.M.A. and T.B.H.—supervision, investigation, and critical review; M.A., P.A., V.B. and F.A.A.—methodology, software, and revision; A.B., S.A.A. and S.D.—original draft. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Grant No. BR10965178 “Development of original domestic drugs with antiviral activity efficient against COVID-19 and influenza” of Ministry of Education and Science of the Republic of Kazakhstan (Andrey Bogoyavlenskiy, Madina Alexyuk, Pavel Alexyuk, Vladimir Berezin from Almaty, Kazakhstan). Taibi Ben Hadda wishes to extend his sincere appreciation to Yassine Zarhloule, President of the University of Mohammed Premier, Morocco, for providing the essential laboratory bioinformatics needed to carry out this research work. The authors would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: (23UQU4320545DSR003).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new compounds reported.

Conflicts of Interest: The authors declare that they have no known competing financial interest or personal relationship that could have appeared to influence the work reported in this paper.

References

1. Atlas, S.A. The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition. *J. Manag. Care Pharm.* **2007**, *13* (Suppl. B), 9–20. [[CrossRef](#)] [[PubMed](#)]
2. Liu, J.; Zhou, Y.; Liu, Y.; Li, L.; Chen, Y.; Liu, Y.; Chen, Y.; Liu, Y.; Feng, Y.; Yosypiv, I.V.; et al. (Pro)renin receptor regulates lung development via the Wnt/ β -catenin signaling pathway. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2019**, *317*, L202–L211. [[CrossRef](#)] [[PubMed](#)]
3. Patel, S.; Rauf, A.; Khan, H.; Abu-Izneid, T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. *Biomed. Pharmacother.* **2017**, *94*, 317–325. [[CrossRef](#)] [[PubMed](#)]
4. Rahimi, Z.; Moradi, M.; Nasri, H. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. *J. Res. Med. Sci.* **2014**, *19*, 1090–1098.
5. Drummond, G.R.; Vinh, A.; Guzik, T.J.; Sobey, C.G. Immune mechanisms of hypertension. *Nat. Rev. Immunol.* **2019**, *19*, 517–532. [[CrossRef](#)]
6. Laghlam, D.; Jozwiak, M.; Nguyen, L.S. Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review. *Cells* **2021**, *10*, 1767. [[CrossRef](#)]
7. Alexandre, J.; Cracowski, J.-L.; Richard, V.; Bouhanick, B. Renin-angiotensin-aldosterone system and COVID-19 infection. *Ann. D'endocrinologie* **2020**, *81*, 63–67. [[CrossRef](#)]
8. Bourgonje, A.R.; Abdulle, A.E.; Timens, W.; Hillebrands, J.L.; Navis, G.J.; Gordijn, S.J.; Bolling, M.C.; Dijkstra, G.; Voors, A.A.; Osterhaus, A.D.; et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *J. Pathol.* **2020**, *251*, 228–248. [[CrossRef](#)]
9. Vaduganathan, M.; Vardeny, O.; Michel, T.; McMurray, V.J.J.; Pfeffer, M.A.; Solomon, S.D. Ren-in-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19. *N. Engl. J. Med.* **2020**, *382*, 1653–1659. [[CrossRef](#)]
10. Shukla, A.K.; Banerjee, M. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update. *High Blood Press. Cardiovasc. Prev.* **2021**, *28*, 129–139. [[CrossRef](#)]
11. Hussain, M.; Jabeen, Q.; Ahmad, F.-U.; Rehman, K.U.; Fatima, M.; Shaukat, S.; Majeed, A.; Barkat, M.Q.; Wu, X. COVID-19 and inhibitors of the renin–angiotensin–aldosterone system. *Expert Rev. Anti-Infect. Ther.* **2020**, *19*, 815–816. [[CrossRef](#)] [[PubMed](#)]

12. Yang, G.; Tan, Z.; Zhou, L.; Yang, M.; Peng, L.; Liu, J.; Cai, J.; Yang, R.; Han, J.; Huang, Y.; et al. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. *Hypertension* **2020**, *76*, 51–58. [[CrossRef](#)] [[PubMed](#)]
13. Huang, Z.; Cao, J.; Yao, Y.; Jin, X.; Luo, Z.; Xue, Y.; Zhu, C.; Song, Y.; Wang, Y.; Zou, Y.; et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. *Ann. Transl. Med.* **2020**, *8*, 430. [[CrossRef](#)] [[PubMed](#)]
14. Conversano, A.; Melillo, F.; Napolano, A.; Fominskiy, E.; Spessot, M.; Ciceri, F.; Agricola, E. Ren-in-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients with SARS-CoV-2 Pneumonia: A Case Series Study. *Hypertension* **2020**, *76*, e10–e12. [[CrossRef](#)] [[PubMed](#)]
15. Covino, M.; De Matteis, G.; Burzo, M.L.; Santoro, M.; Fuorlo, M.; Sabia, L.; Sandroni, C.; Gasbarrini, A.; Franceschi, F.; Gambassi, G. Angiotensin-converting enzyme inhibitors or angio-tensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. *Intern. Med. J.* **2020**, *50*, 1483–1491. [[CrossRef](#)]
16. Zhang, Y.; Tang, L.V. Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. *J. Proteome Res.* **2021**, *20*, 49–59. [[CrossRef](#)]
17. Srivastava, K.; Singh, M.K. Drug repurposing in COVID-19: A review with past, present and future. *Metab. Open* **2021**, *12*, 100121. [[CrossRef](#)]
18. Sahoo, B.M.; Kumar, B.V.V.R.; Sruti, J.; Mahapatra, M.K.; Banik, B.K.; Borah, P. Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection. *Front. Mol. Biosci.* **2021**, *8*, 628144. [[CrossRef](#)]
19. Towler, P.; Staker, B.; Prasad, S.G.; Menon, S.; Tang, J.; Parsons, T.; Ryan, D.; Fisher, M.; Williams, D.; Dales, N.A.; et al. ACE2 X-ray Structures Reveal a Large Hinge-bending Motion Important for Inhibitor Binding and Catalysis. *J. Biol. Chem.* **2004**, *279*, 17996–18007. [[CrossRef](#)]
20. Dutta, K. Allosteric Site of ACE-2 as a Drug Target for COVID-19. *ACS Pharmacol. Transl. Sci.* **2022**, *5*, 179–182. [[CrossRef](#)]
21. Dutta, K.; Elmezayen, A.D.; Al-Obaidi, A.; Zhu, W.; Morozova, O.V.; Shityakov, S.; Khalifa, I. Seq12, Seq12m, and Seq13m, peptide analogues of the spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico study through molecular docking, molecular dynamics simulation, and MM-PB/GBSA calculations. *J. Mol. Struct.* **2021**, *1246*, 131113. [[CrossRef](#)] [[PubMed](#)]
22. Wan, Y.; Shang, J.; Graham, R.; Baric, R.S.; Li, F. Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J. Virol.* **2020**, *94*, e00127-20. [[CrossRef](#)] [[PubMed](#)]
23. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* **2020**, *367*, 1444–1448. [[CrossRef](#)] [[PubMed](#)]
24. Rbaa, M.; Haida, S.; Tuzun, B.; Hichar, A.; El Hassane, A.; Kribii, A.; Lakhrissi, Y.; Ben Hadda, T.; Zarrouk, A.; Lakhrissi, B.; et al. Molecular docking, DFT and POM analyses. *J. Mol. Struct.* **2022**, *1258*, 132688. [[CrossRef](#)]
25. Kawsar, S.M.A.; Almalki, F.A.; Ben Hadd, T.; Laaroussi, H.; Khan, M.A.R.; Hosen, M.A.; Mahmud, S.; Aounti, A.; Maideen, N.M.P.; Heidarizadeh, F.; et al. Potential antifungal activity of novel carbohydrate derivatives validated by POM, molecular docking and molecular dynamic simulations analyses. *Mol. Simul.* **2023**, *49*, 60–75. [[CrossRef](#)]
26. Akkoc, S.; Karatas, H.; Muhammed, M.T.; Kökbudak, Z.; Ceylan, A.; Almalki, F.; Laaroussi, H.; Ben Hadda, T. Drug design of new therapeutic agents: Molecular docking, molecular dynamics simulation, DFT and POM analyses of new Schiff base ligands and impact of substituents on bioactivity of their potential antifungal pharmacophore site. *J. Biomol. Struct. Dyn.* **2022**, *1–14*. [[CrossRef](#)]
27. Abdellattif, M.H.; Elkamhawy, A.; Hagar, M.; Ben Hadda, T.; Shehab, W.S.; Mansy, W.; Belal, A.; Arief, M.M.H.; Hussien, M.A. Novel saccharin analogs as promising antibacterial and anticancer agents: Synthesis, DFT, POM analysis, molecular docking, molecular dynamic simulations, and cell-based assay. *Front. Pharmacol.* **2022**, *13*, 958379. [[CrossRef](#)]
28. Majid, S.A.; Mir, J.M.; Bhat, M.A.; Shalla, A.H.; Pandey, A.; Ben Hadda, T.; Abdellattif, M.H. A pair of carbazate derivatives as novel Schiff base ligands: DFT and POM theory supported spectroscopic and biological evaluation. *J. Biomol. Struct. Dyn.* **2022**, *1–17*. [[CrossRef](#)]
29. Djouad, S.-E.; Berredjem, M.; Aoul, F.Z.H.; Bouchareb, F.; Guerfi, M.; Ben Hadda, T.; Aissaoui, M.; Belhani, B. In silico drug design and molecular docking of novel amidophosphonates and sulfamidophosphonates as inhibitors of urokinase-type plasminogen activator. *J. Indian Chem. Soc.* **2022**, *99*, 100650. [[CrossRef](#)]
30. Munia, N.S.; Hosen, M.A.; Azzam, K.M.A.; Al-Ghorbani, M.; Baashen, M.; Hossain, M.K.; Ali, F.; Mahmud, S.; Shimu, M.S.S.; Almalki, F.A.; et al. Synthesis, antimicrobial, SAR, PASS, molecular docking, molecular dynamics and pharmacokinetics studies of 5'-O-uridine derivatives bearing acyl moieties: POM study and identification of the pharmacophore sites. *Nucleosides Nucleotides Nucleic Acids* **2022**, *41*, 1036–1083. [[CrossRef](#)]
31. Chalkha, M.; Nakkabi, A.; Ben Hadda, T.; Berredjem, M.; El Moussaoui, A.; Bakhouch, M.; Saadi, M.; El Ammari, L.; Almalki, F.A.; Laaroussi, H.; et al. Crystallographic study, biological assessment and POM/Docking studies of pyrazoles-sulfonamide hybrids (PSH): Identification of a combined Antibacterial/Antiviral pharmacophore sites leading to in-silico screening the anti-COVID-19 activity. *J. Mol. Struct.* **2022**, *1267*, 133605. [[CrossRef](#)] [[PubMed](#)]
32. Ben Amor, S.; Mekious, S.; Benfekih, L.A.; Abdellattif, M.H.; Boussebaa, W.; Almalki, F.A.; Ben Hadda, T.; Kawsar, S.M.A. Phytochemical Characterization and Bioactivity of Different Honey Samples Collected in the Pre-Saharan Region in Algeria. *Life* **2022**, *12*, 927. [[CrossRef](#)] [[PubMed](#)]

33. Titi, A.; Touzani, R.; Moliterni, A.; Ben Hadda, T.; Messali, M.; Benabbes, R.; Berredjem, M.; Bouzina, A.; Al-Zaqri, N.; Taleb, M.; et al. Synthesis, structural, biocomputational modeling and antifungal activity of novel armed pyrazoles. *J. Mol. Struct.* **2022**, *1264*, 133156. [[CrossRef](#)]
34. Hosen, M.A.; Munia, N.S.; Al-Ghorbani, M.; Baashen, M.; Almalki, F.A.; Ben Hadda, T.; Ali, F.; Mahmud, S.; Saleh, A.; Laaroussi, H.; et al. Synthesis, antimicrobial, molecular docking and molecular dynamics studies of lauroyl thymidine analogs against SARS-CoV-2: POM study and identification of the pharmacophore sites. *Bioorg. Chem.* **2022**, *125*, 105850. [[CrossRef](#)]
35. Sana, T.; Qayyum, S.; Jabeen, A.; Siddiqui, B.S.; Begum, S.; Siddiqui, R.A.; Hadda, T.B. Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from *Nyctanthes arbor-tristis* Linn. *J. Ethnopharmacol.* **2022**, *293*, 115267. [[CrossRef](#)]
36. Bechlem, K.; Berredjem, M.; Djouad, S.E.; Sothea, T.O.; Bouacida, S.; Marminon, C.; Ben Hadda, T.; Lebreton, J.; Bouzina, A. Novel N-acylsulfamoyl-oxazolidin-2-ones: Synthesis, antitumor activity, X-ray crystallographic study, molecular docking and POM analyses. *J. Mol. Struct.* **2022**, *1262*, 132935. [[CrossRef](#)]
37. Matin, M.M.; Matin, P.; Rahman, R.; Ben Hadda, T.; Almalki, F.A.; Mahmud, S.; Ghoneim, M.M.; Alruwaily, M.; Alshehri, S. Triazoles and Their Derivatives: Chemistry, Synthesis, and Therapeutic Applications. *Front. Mol. Biosci.* **2022**, *9*, 303. [[CrossRef](#)]
38. Lakhri, Y.; Rbaa, M.; Tuzun, B.; Hichar, A.; Anouar, E.H.; Ounine, K.; Almalki, F.; Ben Hadda, T.; Zarrouk, A.; Lakhri, B. Synthesis, structural confirmation, antibacterial properties and bio-informatics computational analyses of new pyrrole based on 8-hydroxyquinoline. *J. Mol. Struct.* **2022**, *1259*, 132683. [[CrossRef](#)]
39. Lafridi, H.; Almalki, F.A.; Ben Hadda, T.; Berredjem, M.; Kawsar, S.M.A.; Alqahtani, A.M.; Esharkawy, E.R.; Lakhri, B.; Zgou, H. In silico evaluation of molecular interactions between macrocyclic inhibitors with the HCV NS3 protease. Docking and identification of antiviral pharmacophore site. *J. Biomol. Struct. Dyn.* **2022**, *41*, 2260–2273. [[CrossRef](#)]
40. Esharkawy, E.R.; Almalki, F.; Ben Hadda, T. In vitro potential antiviral SARS-CoV-19-activity of natural product thymohydroquinone and dithymoquinone from *Nigella sativa*. *Bioorg. Chem.* **2022**, *120*, 105587. [[CrossRef](#)]
41. Hasan, A.H.; Murugesan, S.; Amran, S.I.; Chander, S.; Alanazi, M.M.; Ben Hadda, T.; Shakya, S.; Pratama, M.R.F.; Das, B.; Biswas, S.; et al. Novel thiophene Chalcones-Coumarin as acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, molecular docking, ADMET prediction and molecular dynamics simulation. *Bioorg. Chem.* **2022**, *119*, 105572. [[CrossRef](#)] [[PubMed](#)]
42. Berredjem, M.; Bouzina, A.; Bahadi, R.; Bouacida, S.; Rastija, V.; Djouad, S.-E.; Sothea, T.O.; Almalki, F.A.; Ben Hadda, T.; Aissaoui, M. Antitumor activity, X-ray crystallography, in silico study of some-sulfamido-phosphonates. Identification of pharmacophore sites. *J. Mol. Struct.* **2021**, *1250*, 131886. [[CrossRef](#)]
43. Chalkha, M.; El Moussaoui, A.; Berredjem, M.; Hadda, T.B.; Bouzina, A.; Almalki, F.A.; Saghrouchni, H.; Bakhouch, M.; Saadi, M.; El Ammari, L.E.; et al. Crystallographic Study, Biological Evaluation and DFT/POM/Docking Analyses of Pyrazole Linked Amide Conjugates: Identification of Antimicrobial and Antitumor Pharmacophore Sites. *J. Mol. Struct.* **2021**, *Accepted & under production*.
44. Rbaa, M.; Mequedade, M.; Berkiks, I.; Lakhri, Y.; Mague, J.; El Hessni, A.; Hadda, T.B.; Warad, I.; Zarrouk, A. Toxicological and Pharmacological Studies of a Crystal Structure Derivative of 8-Hydroxyquinoline. *Arab. J. Sci. Eng.* **2021**, *47*, 6889–6900. [[CrossRef](#)]
45. Ben Hadda, T.; Berredjem, M.; Almalki, F.A.; Rastija, V.; Jamalis, J.; Bin Emran, T.; Abu-Izneid, T.; Esharkawy, E.; Rodriguez, L.C.; Alqahtani, A.M. How to face COVID-19: Proposed treatments based on remdesivir and hydroxychloroquine in the presence of zinc sulfate. Docking/DFT/POM structural analysis. *J. Biomol. Struct. Dyn.* **2021**, *40*, 9429–9442. [[CrossRef](#)]
46. Khodair, A.I.; El-Barbary, A.A.; Imam, D.R.; Kheder, N.A.; Elmalki, F.; Ben Hadda, T. Synthesis, antiviral, DFT and molecular docking studies of some novel 1,2,4-triazine nucleosides as potential bioactive compounds. *Carbohydr. Res.* **2021**, *500*, 108246. [[CrossRef](#)] [[PubMed](#)]
47. El Faydy, M.; Dahaieh, N.; Ounine, K.; Rastija, V.; Almalki, F.; Jamalis, J.; Zarrouk, A.; Ben Hadda, T.; Lakhri, B. Synthesis and antimicrobial activity evaluation of some new 7-substituted quinolin-8-ol derivatives: POM analyses, docking, and identification of antibacterial pharmacophore sites. *Chem. Data Collect.* **2020**, *31*, 100593. [[CrossRef](#)]
48. Rbaa, M.; Hichar, A.; Dohare, P.; Anouar, E.H.; Lakhri, Y.; Berredjem, M.; Almalki, F.; Rastija, V.; Rajabi, M.; Ben Hadda, T.; et al. Synthesis, Characterization, Biocomputational Modeling and Antibacterial Study of Novel Pyran Based on 8-Hydroxyquinoline. *Arab. J. Sci. Eng.* **2021**, *46*, 5533–5542. [[CrossRef](#)]
49. Bhat, A.R.; Dongre, R.S.; Almalki, F.A.; Berredjem, M.; Aissaoui, M.; Touzani, R.; Hadda, T.B.; Akhter, M.S. Synthesis, Biological Activity and POM/DFT/Docking Analyses of Annulated Pyrano[2,3-d]pyrimidine Derivatives: Identification of Antibacterial and Antitumor Pharmacophore sites. *Bioorg. Chem.* **2021**, *106*, 104480. [[CrossRef](#)]
50. Rauf, A.; Bawazeer, S.; Raza, M.; El-Sharkawy, E.; Rahman, H.; El-Esawi, M.A.; Uddin, G.; Siddiqui, B.S.; Khalil, A.A.; Molnar, J.; et al. Reversal of multidrug resistance and antitumor promoting activity of 3-oxo-6 β -hydroxy- β -amyrin isolated from *Pistacia integerrima*. *Biocell* **2021**, *45*, 139–147. [[CrossRef](#)]
51. Bawazer, S.; Khan, A.; Rauf, A.; Ben Hadda, T.; Al-Awthman, Y.S.; Bahattab, O.; Rashid, U.; Khan, I.; Nawaz, M.A.; Uddin, S.; et al. POM analysis and computational interactions of 8-hydroxydiospyrin inside active site of protein tyrosine phosphatase 1B. *Biocell* **2021**, *45*, 751–759. [[CrossRef](#)]

52. Thasneema, K.; Dipin, T.; Thayyil, M.S.; Sahu, P.K.; Messali, M.; Rosalin, T.; Elyas, K.; Saharuba, P.; Anjitha, T.; Ben Hadda, T. Removal of toxic heavy metals, phenolic compounds and textile dyes from industrial waste water using phosphonium based ionic liquids. *J. Mol. Liq.* **2020**, *303*, 114645. [[CrossRef](#)]
53. Khalid, S.; Almalki, F.A.; Hadda, T.B.; Bader, A.; Abu-Izneid, T.; Berredjem, M.; Elsharkawy, E.R.; Alqahtani, A.M. Medicinal Applications of Cannabinoids Extracted from *Cannabis sativa* (L.): A New Route in the Fight Against COVID-19? *Curr. Pharm. Des.* **2020**, *27*, 1564–1578. [[CrossRef](#)] [[PubMed](#)]
54. Zaman, Q.; Mahmood Zia, K.M.; Zuber, M.; Jahangir, M.; Almalki, F.; Hadda, T.B.; Rauf, A. A Narrative Study of Herbal Distillates to Evaluate Physicochemical and Microbiological Characteristics. *Acad. J. Food Res.* **2020**, *3*, 15–27.
55. Touzani, R.; Hammouti, B.; El Malki, F.; Benhadda, T. Coronavirus, COVID19, COVID-19 and SARS-CoV: A Global Pandemic, A Short Review. *J. Mater. Environ. Sci.* **2020**, *11*, 736–750.
56. Ben Hadda, T.; Deniz, F.S.S.; Orhan, I.E.; Zgou, H.; Rauf, A.; Mabkhot, Y.N.; Bennani, B.; Emam, D.R.; Kheder, N.A.; Asayari, A.; et al. Spiro Heterocyclic Compounds as Potential Anti-Alzheimer Agents (Part 2): Their Metal Chelation Capacity, POM Analyses and DFT Studies. *Med. Chem.* **2021**, *17*, 834–843. [[CrossRef](#)] [[PubMed](#)]
57. Ben Hadda, T.; Rastija, V.; Almalki, F.; Titi, A.; Touzani, R.; Mabkhot, Y.N.; Khalid, S.; Zarrouk, A.; Siddiqui, B.S. Petra/Osiris/Molinspiration and Molecular Docking Analyses of 3-Hydroxy-Indolin-2-one Derivatives as Potential Antiviral Agents. *Curr. Comput. Aided-Drug Des.* **2020**, *16*, 1. [[CrossRef](#)]
58. Thasneema, K.K.; Thayyil, M.S.; Rosalin, T.; Elyas, K.; Dipin, T.; Sahu, P.K.; Kumar, N.K.; Saheer, V.; Messali, M.; Ben Hadda, T. Thermal and spectroscopic investigations on three phosphonium based ionic liquids for industrial and biological applications. *J. Mol. Liq.* **2020**, *307*, 112960. [[CrossRef](#)]
59. Guerfi, M.; Berredjem, M.; Bouzina, A.; Ben Hadda, T.; Marminon, C.; Rachedi, K.O. Novel α -sulfamidophosphonate analogues of fotemustine: Efficient synthesis using ultrasound under solvent-free conditions. *Mon. Für Chem.-Chem. Mon.* **2020**, *151*, 1859–1865. [[CrossRef](#)]
60. Farghaly, T.A.; Abbas, I.M.; Hassan, W.M.I.; Lotfy, M.S.; Al-Qurashi, N.T.; Ben Hadda, T. Structure Determination and Quantum Chemical Analysis of 1,3-Dipolar Cycloaddition of Nitrile Imines and New Dipolarophiles and POM Analyses of the Products as Potential Breast Cancer Inhibitors. *Russ. J. Org. Chem.* **2020**, *56*, 1258–1271. [[CrossRef](#)]
61. Jamalis, J.; Yusof, F.S.M.; Chander, S.; Wahab, R.A.; Bhagwat, D.P.; Sankaranarayanan, M.; Almalki, F.; Ben Hadda, T. Psoralen Derivatives: Recent Advances of Synthetic Strategy and Pharmacological Properties. *Anti-Inflamm. Anti-Allergy Agents Med. Chem.* **2020**, *19*, 222–239. [[CrossRef](#)]
62. Rakib, A.; Sami, S.A.; Mimi, N.J.; Chowdhury, M.; Eva, T.A.; Nainu, F.; Paul, A.; Shahriar, A.; Tareq, A.M.; Emon, N.U.; et al. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. *Comput. Biol. Med.* **2020**, *124*, 103967. [[CrossRef](#)] [[PubMed](#)]
63. Cruz-Rodríguez, L.; Sanchez, B.; Hochwimmer, B.; Hadda, T.; Almalki, A.; Dilsiz, N.I.H.A.T. How to Evaluate Viral Transmission in Enclosed Areas. Medical Geology saving places from COVID-19. *J. Biosci. Biomed. Eng.* **2020**, *1*, 1–8.
64. Bechlem, K.; Aissaoui, M.; Belhani, B.; Rachedi, K.O.; Bouacida, S.; Bahadi, R.; Djouad, S.-E.; Ben Mansour, R.; Bouaziz, M.; Almalki, F.; et al. Synthesis, X-ray crystallographic study and molecular docking of new α -sulfamidophosphonates: POM analyses of their cytotoxic activity. *J. Mol. Struct.* **2020**, *1210*, 127990. [[CrossRef](#)]
65. Grib, I.; Berredjem, M.; Rachedi, K.O.; Djouad, S.-E.; Bouacida, S.; Bahadi, R.; Ouk, T.-S.; Kadri, M.; Ben Hadda, T.; Belhani, B. Novel N-sulfonylphthalimides: Efficient synthesis, X-ray characterization, spectral investigations, POM analyses, DFT computations and antibacterial activity. *J. Mol. Struct.* **2020**, *1217*, 128423. [[CrossRef](#)]
66. Elsharkawy, E.R.; Almalki, F.; Ben Hadda, T.; Rastija, V.; Lafridi, H.; Zgou, H. DFT calculations and POM analyses of cytotoxicity of some flavonoids from aerial parts of *Cupressus sempervirens*: Docking and identification of pharmacophore sites. *Bioorg. Chem.* **2020**, *100*, 103850. [[CrossRef](#)]
67. Javaid, A.; Hadda, T.B.; Tadjine, N.; Messgo-Moumene, S.; Aissat, A.E.K.; Saddek, D. In vitro evaluation of the antifungal potential of *Zizyphus lotus* L. against toxigenic molds of hydroponic barley. *Mycopath* **2019**, *17*, 33–37.
68. Bawazeer, S.; Rauf, A.; Ali Shah, S.U.; Ullah, N.; Uddin, G.; Khan, H.; Hadda, T.B. Antioxidant and Enzyme inhibitory activities of extracts and phytochemicals isolated from *Pistacia integerrima*. *Z. Arznei Gewurzpfa* **2019**, *23*, 55–58.
69. Amir Khanov, V.; Rauf, A.; Ben Hadda, T.; Ovchinnikov, V.; Trush, V.; Saleem, M.; Raza, M.; Rehman, T.; Zgou, H.; Shaheen, U.; et al. Pharmacophores Modeling in Terms of Prediction of Theoretical Physicochemical Properties and Verification by Experimental Correlations of Carbacylamidophosphates (CAPH) and Sulfanylamidophosphates (SAPH) Tested as New Carbonic Anhydrase Inhibitors. *Mini-Rev. Med. Chem.* **2019**, *19*, 1015–1027. [[CrossRef](#)]
70. Ben Hadda, T.; Rauf, A.; Zgou, H.; Senol, F.S.; Orhan, I.E.; Mabkhot, Y.N.; Althagafi, I.I.; Farghaly, T.A.; Alterary, S. Drug Design of Inhibitors of Alzheimer's Disease (AD): POM and DFT Analyses of Cholinesterase Inhibitory Activity of β -amino di-Carbonyl Derivatives. *Mini-Rev. Med. Chem.* **2019**, *19*, 688–705. [[CrossRef](#)]
71. ELMeskini, I.; Toupet, L.; Daoudi, M.; Kerbal, A.; Moreira, D.R.; Hadda, T.B. Is It Possible for the 2-[(4-chloro-phenyl)-(3,5-dimethylpyrazol-1-yl)-methyl]-malonic acid diethyl ester to Present a Potential Candidate HIV-Integrase Inhibitor on the Basis of Its (O,N,O)-Ligand Structure. *Moroc. J. Heterocycl. Chem.* **2019**, *18*, 36–45. [[CrossRef](#)]
72. Rachedi, K.O.; Ouk, T.-S.; Bahadi, R.; Bouzina, A.; Djouad, S.-E.; Bechlem, K.; Zerrouki, R.; Ben Hadda, T.; Almalki, F.; Berredjem, M. Synthesis, DFT and POM analyses of cytotoxicity activity of α -amidophosphonates derivatives: Identification of potential antiviral O,O-pharmacophore site. *J. Mol. Struct.* **2019**, *1197*, 196–203. [[CrossRef](#)]

73. Rbaa, M.; Jabli, S.; Lakhrissi, Y.; Ouhssine, M.; Almalki, F.; Hadda, T.B.; Messgo-Moumene, S.; Zarrouk, A.; Lakhrissi, B. Synthesis, antibacterial properties and bioinformatics computational analyses of novel 8-hydroxyquinoline derivatives. *Heliyon* **2019**, *5*, e026892. [CrossRef] [PubMed]
74. Rachedi, K.O.; Bahadi, R.; Aissaoui, M.; Ben Hadda, T.; Belhani, B.; Bouzina, A.; Berredjem, M. DFT Study, POM Analyses and Molecular Docking of Novel Oxazaphosphinanes: Identification of Antifungal Pharmacophore Site. *Indones. J. Chem.* **2020**, *20*, 440–450. [CrossRef]
75. Titi, A.; Messali, M.; Alqurashy, B.A.; Touzani, R.; Shiga, T.; Oshio, H.; Fettouhi, M.; Rajabi, M.; Almalki, F.A.; Ben Hadda, T. Synthesis, characterization, X-ray crystal study and bioactivities of pyrazole derivatives: Identification of antitumor, antifungal and antibacterial pharmacophore sites. *J. Mol. Struct.* **2020**, *1205*, 127625. [CrossRef]
76. Rbaa, M.; Oubihi, A.; Anouar, E.H.; Ouhssine, M.; Almalki, F.; Ben Hadda, T.; Zarrouk, A.; Lakhrissi, B. Synthesis of new heterocyclic systems oxazino derivatives of 8-Hydroxyquinoline: Drug design and POM analyses of substituent effects on their potential antibacterial properties. *Chem. Data Collect.* **2019**, *24*, 100306. [CrossRef]
77. Jarrahpour, A.; Heiran, R.; Sinou, V.; Latour, C.; Bouktab, L.D.; Brunel, J.M.; Sheikh, J.; Ben Hadda, T. Synthesis of New β -Lactams Bearing the Biologically Important Morpholine Ring and POM Analyses of Their Antimicrobial and Antimalarial Activities. *Iran. J. Pharm. Res.* **2019**, *18*, 34–48. [CrossRef]
78. Kamal, A.M.; Abdelhady, M.; Ben Hadda, T. Two Novel Flavone C-Glycosides Isolated from *Afrocarpus Gracilior*: Pom Analyses and in Vitro Cytotoxic Activity Against Hepatocellular Carcinoma. *Int. J. Pharm. Pharm. Sci.* **2019**, *11*, 57–62. [CrossRef]
79. Dongre, R.S.; Meshram, J.S.; Selokar, R.S.; Almalki, F.A.; Ben Hadda, T. Antibacterial activity of synthetic pyrido[2,3-*d*]pyrimidines armed with nitrile groups: POM analysis and identification of pharmacophore sites of nitriles as important pro-drugs. *New J. Chem.* **2018**, *42*, 15610–15617. [CrossRef]
80. Ben Hadda, T.; Talhi, O.; Silva, A.S.; Senol, F.S.; Orhan, I.E.; Rauf, A.; Mabkhot, Y.; Bachari, K.; Warad, I.; Farghaly, T.A.; et al. Cholinesterase Inhibitory Activity of Some semi-Rigid Spiro Heterocycles: POM Analyses and Crystalline Structure of Pharmacophore Site. *Mini-Rev. Med. Chem.* **2018**, *18*, 711–716. [CrossRef]
81. Ullah, M.A.; Adeel, M.; Tahir, M.N.; Rauf, A.; Akram, M.; Hadda, T.B.; Mabkhot, Y.; Muhammad, N.; Naseer, F.; Mubarak, M.S. Synthesis, Structural Characterization and Antinociceptive Activities of New Arylated Quinolines via Suzuki-Miyaura Cross Coupling Reaction. *Med. Chem.* **2017**, *13*, 780–786. [CrossRef]
82. Khan, H.; Khan, Z.; Amin, S.; Mabkhot, Y.N.; Mubarak, M.S.; Ben Hadda, T.; Maione, F. Plant bioactive molecules bearing glycosides as lead compounds for the treatment of fungal infection: A review. *Biomed. Pharmacother.* **2017**, *93*, 498–509. [CrossRef] [PubMed]
83. Hakkou, Z.; Maciuk, A.; Leblais, V.; Bouanani, N.E.; Mekhfi, H.; Bnouham, M.; Aziz, M.; Ziyat, A.; Rauf, A.; Hadda, T.B.; et al. Antihypertensive and vasodilator effects of methanolic extract of *Inula viscosa*: Biological evaluation and POM analysis of cynarin, chlorogenic acid as potential hypertensive. *Biomed. Pharmacother.* **2017**, *93*, 62–69. [CrossRef] [PubMed]
84. Chander, S.; Tang, C.-R.; Al-Maqtari, H.M.; Jamalis, J.; Penta, A.; Ben Hadda, T.; Sirat, H.M.; Zheng, Y.-T.; Sankaranarayanan, M. Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives. *Bioorg. Chem.* **2017**, *72*, 74–79. [CrossRef] [PubMed]
85. Al-Maqtari, H.M.; Jamalis, J.; Ben Hadda, T.; Sankaranarayanan, M.; Chander, S.; Ahmad, N.A.; Sirat, H.M.; Althagafi, I.I.; Mabkhot, Y.N. Synthesis, characterization, POM analysis and antifungal activity of novel heterocyclic chalcone derivatives containing acylated pyrazole. *Res. Chem. Intermed.* **2016**, *43*, 1893–1907. [CrossRef]
86. Mabkhot, Y.; Arfan, M.; Zgou, H.; Genc, Z.K.; Genc, M.; Rauf, A.; Bawazeer, S.; Ben Hadda, T. How to improve antifungal bioactivity: POM and DFT study of some chiral amides derivatives of diacetyl-L-tartaric acid and amines. *Res. Chem. Intermed.* **2016**, *42*, 8055–8068. [CrossRef]
87. Rauf, A.; Uddin, G.; Siddiqui, B.S.; Khan, H.; Shah, S.U.A.; Ben Hadda, T.; Mabkhot, Y.N.; Farooq, U.; Khan, A. Antinociceptive and anti-inflammatory activities of flavonoids isolated from *Pistacia integerrima* galls. *Complement. Ther. Med.* **2016**, *25*, 132–138. [CrossRef]
88. Sajid, Z.; Ahmad, M.; Aslam, S.; Ashfaq, U.A.; Zahoor, A.F.; Saddique, F.A.; Parvez, M.; Hameed, A.; Sultan, S.; Zgou, H.; et al. Novel Armed Pyrazolobenzothiazine Derivatives: Synthesis, X-ray Crystal Structure and POM analyses of Biological Activity Against Drug Resistant Clinical Isolate of *Staphylococcus aureus*. *Pharm. Chem. J.* **2016**, *50*, 172–180. [CrossRef]
89. Mabkhot, Y.N.; Alatibi, F.; El-Sayed, N.N.E.; Al-Showiman, S.; Kheder, N.A.; Wadood, A.; Rauf, A.; Bawazeer, S.; Ben Hadda, T. Antimicrobial Activity of Some Novel Armed Thiophene Derivatives and Petra/Osiris/Molinspiration (POM) Analyses. *Molecules* **2016**, *21*, 222. [CrossRef]
90. Tatar, E.; Şenkardes, S.; Sellitepe, H.E.; Küçükgülzel, G.; Karaoğlu, A.; Bozdeveci, A.; DE Clercq, E.; Pannecouque, C.; BEN Hadda, T.; Küçükgülzel, I. Synthesis, and prediction of molecular properties and antimicrobial activity of some acylhydrazones derived from *N*-(arylsulfonyl)methionine. *Turk. J. Chem.* **2016**, *40*, 510–534. [CrossRef]
91. Hadda, T.B. Ranking for Scientists. 2023. Available online: <https://www.adscientificindex.com/scientist/taibi-ben-hadda/91200> (accessed on 27 April 2023).
92. Hadda, T.B. Research Excellence Awards. 2018. Available online: <https://www.maroc.ma/fr/actua-lites/research-excellence-awards-une-vingtaine-de-travaux-de-recherche-et-dinnovation-primés> (accessed on 27 April 2023).
93. Mooers, B.H.M.; Brown, M.E. Templates for writing PyMOL scripts. *Protein Sci.* **2021**, *30*, 262–269. [CrossRef]
94. Barber, R.D. Software to Visualize Proteins and Perform Structural Alignments. *Curr. Protoc.* **2021**, *1*, e292. [CrossRef] [PubMed]

95. Mooers, B.H.M. Shortcuts for faster image creation in PyMOL. *Protein Sci.* **2020**, *29*, 268–276. [[CrossRef](#)]
96. Goodsell, D.S.; Sanner, M.F.; Olson, A.J.; Forli, S. The AutoDock suite at 30. *Protein Sci.* **2021**, *30*, 31–43. [[CrossRef](#)] [[PubMed](#)]
97. Mohamed, K.; Yazdanpanah, N.; Saghadzadeh, A.; Rezaei, N. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. *Bioorg. Chem.* **2021**, *106*, 104490. [[CrossRef](#)]
98. Tang, S.; Chen, R.; Lin, M.; Lin, Q.; Zhu, Y.; Ding, J.; Hu, H.; Ling, M.; Wu, J. Accelerating AutoDock Vina with GPUs. *Molecules* **2022**, *27*, 3041. [[CrossRef](#)]
99. Kwofie, S.K.; Broni, E.; Asiedu, S.O.; Kwarko, G.B.; Dankwa, B.; Enninful, K.S.; Tiburu, E.K.; Wilson, M.D. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin. *Molecules* **2021**, *26*, 406. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.